BE902783A - Appareil et procede pour l'administration pulsee d'agents favorisant la croissance. - Google Patents

Appareil et procede pour l'administration pulsee d'agents favorisant la croissance.

Info

Publication number
BE902783A
BE902783A BE0/215282A BE215282A BE902783A BE 902783 A BE902783 A BE 902783A BE 0/215282 A BE0/215282 A BE 0/215282A BE 215282 A BE215282 A BE 215282A BE 902783 A BE902783 A BE 902783A
Authority
BE
Belgium
Prior art keywords
growth promoting
analogues
promoting agents
growth hormone
pulsed delivery
Prior art date
Application number
BE0/215282A
Other languages
English (en)
Original Assignee
Linkie Daniel M
Thorner Michael O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linkie Daniel M, Thorner Michael O filed Critical Linkie Daniel M
Publication of BE902783A publication Critical patent/BE902783A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procédé et appareil à programme (18, 21, 23) pour le traitement efficace d'un animal vivant, suivant lequel on administre une dose dynamique de facteur de dégagement de l'hormone de croissance ou de ses analogues ou on administre à titre chronique l'hormone de croissance ou ses analogues en régime subdésensibilisant. Procédé de diagnostic chez l'animal vivant atteint d'une insenibilité de l'hypophyse antérieure à l'égard du facteur de dégagement de l'hormone de croissance ou de ses analogues.
BE0/215282A 1984-06-29 1985-06-28 Appareil et procede pour l'administration pulsee d'agents favorisant la croissance. BE902783A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/626,400 US4747825A (en) 1984-06-29 1984-06-29 Apparatus and methodology for pulsed administration of growth promoting agents

Publications (1)

Publication Number Publication Date
BE902783A true BE902783A (fr) 1985-10-16

Family

ID=24510242

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/215282A BE902783A (fr) 1984-06-29 1985-06-28 Appareil et procede pour l'administration pulsee d'agents favorisant la croissance.

Country Status (16)

Country Link
US (1) US4747825A (fr)
EP (1) EP0190199A4 (fr)
JP (1) JPS61502519A (fr)
AU (1) AU4605385A (fr)
BE (1) BE902783A (fr)
BR (1) BR8506785A (fr)
DK (1) DK294685A (fr)
FI (1) FI852516L (fr)
IL (1) IL75671A0 (fr)
MW (1) MW686A1 (fr)
NO (1) NO852603L (fr)
OA (1) OA08214A (fr)
PT (1) PT80738B (fr)
RO (1) RO95012A (fr)
WO (1) WO1986000233A1 (fr)
ZA (1) ZA854916B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089472A (en) * 1988-01-26 1992-02-18 Laboratorios Serono S.A. Use of growth hormone releasing factor for improving mental function
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5065747A (en) * 1989-11-21 1991-11-19 University Of South Florida Method for improving the accuracy of diagnosis of growth hormone deficiency
US5428013A (en) * 1991-01-04 1995-06-27 Mugica; Jesus D. Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
CA2174737C (fr) * 1993-10-29 2008-04-22 Douglas V. Faller Compositions physiologiquement stables d'acide butyrique, de sels et de derives d'acide butyrique, utilisees comme agents antineoplasiques
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
AU3889197A (en) 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
US6403647B1 (en) 1996-07-26 2002-06-11 Susan P. Perrine Pulsed administration of compositions for the treatment of blood disorders
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
WO1999040883A2 (fr) * 1998-02-11 1999-08-19 Faller Douglas V Compositions et techniques de traitement de la mucoviscidose
WO2004022593A2 (fr) * 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2010105112A1 (fr) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Détection d'acides gras à chaîne courte dans des échantillons biologiques
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
EP2509418A4 (fr) 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc Procédés et régimes à faible dose pour traiter des troubles des globules rouges
WO2011113013A2 (fr) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Procédés et compositions pour le traitement d'états viraux ou induits par des virus
EP2670426B1 (fr) 2011-01-31 2017-05-10 The General Hospital Corporation Molécules trail multimodales et leurs utilisations en thérapies cellulaires
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
US20140271657A1 (en) 2011-10-12 2014-09-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2013082275A1 (fr) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibiteurs de phosphodiestérases 11 (pde11) et procédés d'utilisation pour augmenter la production de cortisol
US10513540B2 (en) 2012-07-31 2019-12-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
US20150273056A1 (en) 2012-10-12 2015-10-01 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
WO2014130922A1 (fr) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions et procédés pour le traitement d'infections fongiques
CA2924141C (fr) 2013-08-22 2022-06-07 The General Hospital Corporation Derives d'oxazole et de thiazole substitues par 5-amino 4-cyano utilisesen tant qu'inhibiteurs de la 12/15-lipoxygenase-humaine
EP3038625A4 (fr) 2013-08-29 2017-08-23 Trustees of Boston University Produits métaboliques intermédiaires pour potentialiser des antibiotiques aminoglycosides dans des infections bactériennes
EP4053560A1 (fr) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions et procédés de modulation d'une réponse immunitaire
EP3079712B1 (fr) 2013-12-11 2022-02-02 The General Hospital Corporation Utilisation de protéines d'hormone anti-mullerienne (amh) pour la contraception et la préservation de la réserve ovarienne
WO2015143343A2 (fr) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique
AU2015249666A1 (en) 2014-04-25 2016-11-17 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
US20170044257A1 (en) 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
WO2016044707A1 (fr) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions et procédés de traitement de la fibrose
EP3244926B8 (fr) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Traitement du cancer avec des anticorps monoclonaux anti-lap
EP4194001A1 (fr) 2015-04-22 2023-06-14 Cedars-Sinai Medical Center Oligopeptides amers administrés par voie entérique pour le traitement du diabète de type 2 et de l'obésité
EP3303286B1 (fr) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Composés qui se lient à rela de nf-kb pour utilisation dans le traitement de cancer
US20180185345A1 (en) 2015-06-19 2018-07-05 Trustees Of Boston University Methods and compositions for treating herpesvirus induced conditions
MX2018001075A (es) 2015-07-28 2019-04-15 Vyome Therapeutics Ltd Agentes terapeuticos y profilacticos antibacterianos.
EP3355909B1 (fr) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Méthodes de traitement de maladies à médiation par les macrophages pro-inflammatoires positifs à l'erbb4
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018067991A1 (fr) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation de nouvelles cibles de points de contrôle immunitaires
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2020102454A1 (fr) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Peptides ciblant le cd40 et leurs utilisations
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498228A (en) * 1967-05-01 1970-03-03 Charles A Blumle Portable infusion pump
US3559644A (en) * 1967-12-14 1971-02-02 Robert F Shaw Liquid infusion apparatus
US3809871A (en) * 1972-12-01 1974-05-07 Nasa Programmable physiological infusion
US4273122A (en) * 1976-11-12 1981-06-16 Whitney Douglass G Self contained powered injection system
US4313439A (en) * 1980-03-24 1982-02-02 Biotek, Inc. Automated, spring-powered medicament infusion system
DE3015777A1 (de) * 1980-04-24 1981-10-29 Ferring Arzneimittel Gmbh, 2300 Kiel Vorrichtung zur intermittierenden pulsatorischen applikation von fluessigen arzneimitteln
US4306553A (en) * 1980-07-22 1981-12-22 The Regents Of The University Of Minnesota Method of maintaining the fluidity of hormone solutions for parenteral administration
US4517181A (en) * 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4529595A (en) * 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs

Also Published As

Publication number Publication date
OA08214A (en) 1987-10-30
FI852516L (fi) 1985-12-30
EP0190199A4 (fr) 1987-12-01
AU4605385A (en) 1986-01-24
IL75671A0 (en) 1985-10-31
ZA854916B (en) 1986-02-26
JPS61502519A (ja) 1986-11-06
NO852603L (no) 1985-12-30
DK294685D0 (da) 1985-06-28
PT80738B (en) 1986-12-11
DK294685A (da) 1985-12-30
PT80738A (en) 1985-07-01
FI852516A0 (fi) 1985-06-26
EP0190199A1 (fr) 1986-08-13
MW686A1 (en) 1987-03-11
US4747825A (en) 1988-05-31
BR8506785A (pt) 1986-11-25
RO95012A (fr) 1988-09-15
WO1986000233A1 (fr) 1986-01-16

Similar Documents

Publication Publication Date Title
BE902783A (fr) Appareil et procede pour l'administration pulsee d'agents favorisant la croissance.
Stern et al. Pituitary-adrenal responsiveness during lactation in rats
Adams et al. Hyperthyroidism in Tasmania following iodide supplementation: measurements of thyroid-stimulating autoantibodies and thyrotropin
Edmonds et al. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine
Rosenberg et al. Prophylaxis of postoperative leg vine thrombosis by low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial.
DE69031279D1 (de) Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
Burke The triiodothyronine suppression test
Smith et al. Increasing the effectiveness of gold therapy in rheumatoid arthritis
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
Constas The effects of adrenaline, noradrenaline, and isoprenaline on parkinsonian tremor
DE3880587D1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
NZ209743A (en) Use of growth hormone to enhance ruminant mammary development
Wilson et al. Thyroid hormone and brain function: I. The EEG in hyperthyroidism with observations on the effect of age, sex, and reserpine in the production of abnormalities
Grund et al. Hyperthyroxinemia in patients receiving thyroid replacement therapy
JACOBS Observations of neuropathic (Charcot) joints occurring in diabetes mellitus
Innerfield et al. Bradykinin antagonism following oral protease therapy
Singer Latency of pancreatic fluid secretory response to intestinal stimulants in the dog.
Burhol et al. Single subcutaneous doses of histamine and pentagastrin in gastric fistula chickens
Aub Parathyroid hormone therapy
KRUGMAN et al. TRH test as an index of suppression compared with the thyroid radioiodine uptake in euthyroid goitrous patients treated with thyroxine
Griswold et al. Lymphocyte responses to phytohemagglutinin in rheumatoid arthritis and glomerulonephritis and the effects of immunosuppression
Fleischer Effect of oxytetracycline and chloramphenicol on the exocrine pancreatic function in the rat
SUTRO et al. Basis and treatment of calcification of tendinocapsular tissues, especially the supraspinatus tendon
Haggendal et al. The effect of triiodothyronine treatment on the catecholamine content of the blood during infusion of adrenaline in man
Obel A literary review on bovine fluorosis

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THORNER MICHAEL O.

Effective date: 19880630

Owner name: LINKIE DANIEL M

Effective date: 19880630